1. Accueil
  2. Victoria Leclercq
  3. Victoria Leclercq

Onglets principaux

Rechercher
Limit to
Exporter 12 resultats:
Filtres: Auteur is V Leclercq
2025
Telemedicine in cancer care: lessons from COVID-19 and solutions for Europe, Gottlob, Anita, Schmitt Tugce, Sønderskov Frydensberg, Morten, Rosińska Magdalena, Leclercq V, and Habimana Katharina , European Journal of Public Health, Mar-01-2025, (2025)
2024
Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022, Van der Heyden, Johan, Leclercq V, Duysburgh Els, Cornelissen Laura, Desombere Isabelle, Inge Roukaerts, and Gisle Lydia , Arch Public Health, 2024 May 15, Volume 82, Issue 1, (2024)
Prevalence of SARS-CoV-2 antibodies and associated factors in the adult population of Belgium: a general population cohort study between March 2021 and April 2022, Van der Heyden, Johan, Leclercq V, Duysburgh Els, Cornelissen Laura, Desombere Isabelle, Inge Roukaerts, and Gisle Lydia , Archives of Public Health, Jan-12-2024, Volume 82, Issue 1, (2024)
2022
Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study, Leclercq, V, Van den Houte Nayema, Gisle Lydia, Roukaerts Inge, Barbezange Cyril, Desombere I, Duysburgh Els, and Van der Heyden Johan , Viruses, Jan-05-2022, Volume 14, Issue 5, (2022)
Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study., Leclercq, V, Van den Houte Nayema, Gisle Lydia, Roukaerts Inge, Barbezange Cyril, Desombere I, Duysburgh Els, and Van der Heyden Johan , Viruses, 2022 04 28, Volume 14, Issue 5, (2022)
Prevalence of anti-SARS-CoV-2 antibodies in the general population in Belgium : Results of the second data collection (28/09/21-23/02/22), Van den Houte, Nayema, Leclercq V, Gisle Lydia, and Van der Heyden Johan , 21/04/2022, Brussels, Belgium, p.13, (2022)
2021
Prevalence of anti-SARS-CoV-2 antibodies in the general population in Belgium: First results of the SalivaHIS study, Leclercq, V, Van den Houte Nayema, Gisle Lydia, and Van der Heyden Johan , 25/11/2021, Brussels, Belgium, p.80, (2021)
Prevalence of metabolic syndrome and its risk factors among Belgian adults, Leclercq, V, Drieskens Sabine, and Van der Heyden Johan , EUPHA, (2021)
Sixième enquête de santé COVID-19 : résultats préliminaires, Berete, Finaba, Braekman Elise, Bruggeman Helena, Charafeddine Rana, Demarest Stefaan, Drieskens Sabine, Gisle Lydia, Hermans Lize, Leclercq V, and Van der Heyden Johan , 13/04/2021, (2021)
Zesde COVID-19-Gezondheidsenquête. Eerste resultaten, Berete, Finaba, Braekman Elise, Bruggeman Helena, Charafeddine Rana, Demarest Stefaan, Drieskens Sabine, Gisle Lydia, Hermans Lize, Leclercq V, and Van der Heyden Johan , 13/04/2021, (2021)
0
Inequities to the access to and use of telemedicine among cancer patients in Europe: A scoping review, Leclercq, V, Vandervliet Léopold, Schmitt Tugce, Van den Bulcke Marc, and Delnord Marie , (0)
Prevalence of anti-SARS-CoV-2 antibodies in the general population in Belgium, March 2021 - April 2022, Leclercq, V, Gisle Lydia, Van den Houte Nayema, and Van der Heyden Johan , (0)

QR code

QR code for this page URL